Commercialization: Page 12
-
PharmaVoice Team/PharmaVoice
Mission: Disrupt Health Disparities — Dr. Altovise Ewing
I envision a future of healthcare where genetics is used to advance health equity. I deem this a critical and possible mission, and believe our work at Genentech is a step in the right direction to getting us there. Dr. Altovise Ewing’s passion for health equity is personal. As a Black woman rais...
By Altovise T. Ewing • March 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Real-World Evidence: Realizing the Benefits of RWE
The real-world evidence (RWE) market has grown significantly in recent years, supported by a favorable regulatory environment. Increasingly, companies recognize that real-world evidence (RWE) presents an opportunity to improve efficiency and innovation. One of the biggest challenges for pharma co...
By PharmaVoice Team • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Commanders & Chiefs: Chief Patient Officers
More and more companies are elevating patient-facing roles to the C-Suite, as a result, these key roles continue to expand and evolve to address the goals of patient-centricity and patient engagement. Dr. Julie Gerberding Merck Respecting Voices Across the Spectrum of Advocacy The concept of pati...
By PharmaVoice Team • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Executive Perspective: A Learning Model: A Deployment Strategy for the Future
Throughout her 20-year-plus career, Jaime Thompson has become an expert in driving client launches and brand success through commercial and medical channels. Her deep analytical expertise provides customers with innovative ways to execute on their brand strategies — from the first launch of an or...
By Jaime Thompson • March 1, 2021 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Celebrating firsts… Last month we witnessed Kamala Harris sworn in as the first woman, Black, and South Asian American as the 49th Vice President of the United States by Supreme Court Justice Sonia Sotomayor, the first Latina to be named to the bench and just the third woman to be named to the hi...
By Taren Grom • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Upfront
Ogilvy Captures Response in Historic Swearing In Ogilvy captured girls across the country at the moment that Kamala Harris was sworn in as the first woman, Black, and South Asian American as the 49th Vice President of the United States. Girl Up changemakers can be seen in the video watching this ...
By PharmaVoice Team • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
HealthTech
Heat Monitoring Systems Could Help COVID-19 Diagnosis Trend Watch: Wearables Contribute to Identifying COVID-19 A smart ring, being developed by Oura, that generates continuous temperature data may foreshadow COVID-19, even in cases when infection is not suspected. The device, which may be a bett...
By PharmaVoice Team • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
Google DeepMind’s Protein Folding Algorithms Solve Structures Faster Than Ever Trend Watch: From Predicting COVID Patient Outcomes to Protein Structures, AI An AI network developed by Google AI offshoot DeepMind has made a gargantuan leap in solving one of biology’s grandest challenges — determi...
By PharmaVoice Team • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Healthcare Investment Trends
Global healthcare funding hit a new record in 2020: a total of $80.6 billion in equity funding was raised across more than 5,500 deals, according to CB Insights. North America, Asia, and Europe all saw a boost in funding year-over-year. There were 187 healthcare mega-rounds ($100M+) in 2020 — a n...
By Kim Ribbink and Taren Grom • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Cutting Through the Noise
COVID-19 has complicated the marketing environment, and experts suggest ways to stand out in an ever-changing climate. The effects of COVID-19 have given a good shake to an already ever-changing marketing landscape, and for pharma marketers it is more difficult than ever to cut through the resoun...
By Robin Robinson • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Rare Disease: Tackling the Barriers to Rare Disease Treatments
Efforts to address the approximately 7,000 rare diseases worldwide have intensified as life-sciences companies increasingly turn their attention to these conditions. According to some analysts reports, orphan drugs could account for one-fifth of global prescription sales by 2024. This increase in...
By PharmaVoice Team • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Five Recommendations to Make Trials More Child-Centric
Increasing Engagement of the Pediatric Population. Rare disease research is an increasingly competitive sector of the clinical research landscape. While rare diseases individually affect a relatively small number of patients, as a category these diseases affect millions of people – and half of th...
By Robin Burges • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Unlocking Hope for Patients with Rare Diseases
One of the most insidious characteristics of rare diseases is how isolating they can be for patients and their caregivers. Those with a rare disease don’t enjoy the social sport of comparing cholesterol numbers among friends at a dinner party. Theirs is a much lonelier path of confusing symptoms,...
By David Ormesher • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Impactful Rare Disease Campaigns Are Grounded in Medically Inspired Approaches
Patient-rooted strategies are essential in rare disease communication and commercialization. No matter what stage a company is at, or what therapeutic area it is serving, one thing is certain: Rare diseases present unique commercialization and communication challenges that require a deep understa...
By Ian DeMeritt • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Opening Doors to Clinical Trial Innovation
New opportunities are available in spite of a year not worth repeating. Although 2020 was an incredibly challenging year for conducting clinical research studies due to COVID-19, many leaders acknowledge it forced the industry to rethink processes and creatively address the barriers that have oft...
By Nina Wachsman • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Success in Rare Diseases — Connections Matter
When it comes to rare diseases, the scarcity of patients requires us to make every connection matter. In the United States, a rare disease is defined as a condition affecting fewer than 200,000 people, a definition created by the U.S. Congress in the Orphan Drug Act of 1983. Rare diseases then be...
By Amy Graham • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
A Glimmer of Hope for Rare Disease Patients & Beyond: Gene Therapy
Considerations and Challenges in an Evolving Market Two decades ago, as gene therapy was emerging as the next great frontier in modern medicine, the field was forced to recon with tragedy: the death of Jesse Gelsinger as a direct result of a gene therapy treatment he was given. For Jesse, the nov...
By Pete Robinson • Feb. 1, 2021 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
Lighting the way… As we say good riddance to 2020, and look toward a more optimistic 2021, we are starting to see some glimmers of light and a more hopeful future. Granted, as they say, hope is not a strategy, but there is hope. At this moment, two COVID-19 vaccines have been approved and million...
By Taren Grom • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
Trend Tracking
The industry is moving fast, and our community of experts weigh in on the top trends they are watching. Welcome to 2021. This is the first in a series of Trend Tracking updates that we will be publishing throughout the year. Given the current state of, well everything, we decided to highlight th...
By PharmaVoice Team • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
Artificial Intelligence
AdventHealth, Berg tap AI to Reduce Mortality in COVID-19 Patients Trend Watch: Collaborations Combine AI and RWE to Combat COVID and Other Diseases Berg, a clinical-stage biotech that employs patient biology and AI to research diseases and develop innovative treatments, is collaborating with Adv...
By PharmaVoice Team • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: Virtual Health: A Virtual Awakening: COVID-19 Brings Healthcare Revolution
Healthcare delivery has undergone a dramatic shift in the wake of the COVID-19 pandemic. Virtual health has been around for more than a decade, but adoption has been slow. However, thanks to advances in technology and the global pandemic that have impacted all areas of health, healthcare is being...
By PharmaVoice Team • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
How to Enhance Provider and Patient Engagement in Tech-Savvy Healthcare
Pharmaceutical representatives have always been a welcomed resource and consistent office visitor for healthcare providers (HCPs). Today, in a world operating largely virtually, pharma reps are re-strategizing HCP engagement in the same way providers are rethinking patient outreach. For physician...
By Peter Marchesini • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
The Explosion of Virtual Health in the Field of Mental Health
This year has been an incredibly difficult and stressful one due to the COVID-19 pandemic, and for those of us in the United States, the pressures have only been exacerbated by ongoing incidents of racial injustice and political turmoil. These circumstances have all placed an enormous amount of p...
By Kate Cronin • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
Combating Telehealth Distractions With Innovation
It’s unsurprising that 2020 has spurred rapid growth for digital health. COVID-19 forced patients and healthcare professionals alike to rethink healthcare access, delivery, and management, with technology central to this reimagination. There was no brighter star in this new world than telemedicin...
By Chris Jankoski • Jan. 1, 2021 -
PharmaVoice Team/PharmaVoice
SHOWCASE: High-Science Brands: Laying the Groundwork for High-Science Brands
Cell and gene therapies, immunotherapies, RNA interference (RNAi) – innovative scientific breakthroughs have the potential to change the course of treatment for severe diseases such as cancer and devastating rare diseases. The gene therapy market is predicted to rise to $35.67 billion by 2027 fr...
By PharmaVoice Team • Jan. 1, 2021
Previous
